MarketWatch · Feb 22, 2023
Lucira Health files for bankruptcy, will pursue sale
Medical technology company Lucira Health Inc. filed for chapter 11 bankruptcy protection and plans to pursue a sale of its business under Section 363.
LH
NASDAQ · LHDX
Lucira Health, Inc.
Healthcare · Medical - Devices
$0.45
Up+$0.00 (+0.00%)
Updated Aug 15, 2026, 4:59 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 18.36M
- P/E ratio
- -0.24
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 36.26M
- Avg. volume
- 21.15M
Price performance
LHDX price history
1M range · 0 trading sessions · Daily adjusted prices
LHDX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest LHDX news
The latest Smart Investors Daily articles mentioning LHDX.
Stock researchCompany · Overview
LHDX research
Overview
Company profile and research snapshot.
Company profile
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 4, 2021 | William Blair | Market Perform | — |
| Apr 13, 2021 | B of A Securities | Underperform | — |
| Mar 2, 2021 | William Blair | Outperform | — |
| Mar 2, 2021 | B of A Securities | Neutral | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Feb 22, 2023
Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
No debtor-in-possession financing required as the Company intends to fund operations and the sale process with available cash on hand. No debtor-in-possession financing required as the Company intends to fund operations and the sale process with available cash on hand.
Zacks Investment Research · Feb 2, 2023
The Zacks Analyst Blog Highlights AppHarvest, Lucira Health, Lucid Group, Life Time Group and Ameriprise Financial
AppHarvest, Lucira Health, Lucid Group, Life Time Group and Ameriprise Financial are included in this Analyst Blog.
Zacks Investment Research · Feb 1, 2023
5 Big Winners as Wall Street Wraps Up Strong January Gains
AppHarvest (APPH), Lucira Health (LHDX), Lucid Group (LCID), Life Time Group (LTH) & Ameriprise Financial (AMP) not only have made the most of the January rally but also are poised to gain further this year.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
